USPTO 2015–2025 USPTO PatentsView US Corporation

NxStage Medical, Inc.

USPTO PatentsView assignee record - 141 granted patents across 34 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

RSS updates for this company

The verdict

According to USPTO PatentsView, Nxstage ranks #2,746 of 49,997 tracked US assignees by granted-patent volume, with 141 patents across 34 technology areas.

#2,746
of 49,997 US assignees by volume
Top 7%
by Innovation Score (54.8/100)
14.3
avg claims per patent
+121%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R2746 · US Corporation #2,746 · 141 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-MID 141 grants
  • TOP-DECILE #2,746/49,997
  • PHOTO-FINISH Kemet
  • CPC-FOCUS A61M · 34 areas
  • INNOV-PAR 54.8/100
  • CLAIMS-RICH 14.3 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-SURGE +121% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Kemet Electronics Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around Nxstage

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Nxstage's Innovation Score is 54.8/100 (top 7% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where Nxstage's grants concentrate

NxStage Medical, Inc. is a focused PatentsView assignee: 34 CPC subclasses with 95% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2024 (27 grants) versus a trough of 2 in 2015. By volume, Nxstage sits between Kemet Electronics Corporation and TomTom International B.V..

Nxstage's three-year grant acceleration

From 2019–2021 to 2022–2024, NxStage Medical, Inc. moved from 44 to 56 grants (1.27x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #681. See the growth leaderboard.

Who files at NxStage's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows NxStage holds 141 patents at rank #2,746, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near NxStage

By rank, the assignees closest to #2,746 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in NxStage's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for NxStage, neither rank-band nor same-CPC leaders (those blocks stay above).

Nxstage's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

55 Top 7% higher than 93% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0102030 20152016201720182019202020212022202320242025 16
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
NxStage Medical, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 2 1.4%
2016 4 2.8%
2017 12 8.5%
2018 7 5.0%
2019 14 9.9%
2020 14 9.9%
2021 16 11.3%
2022 14 9.9%
2023 15 10.6%
2024 27 19.1%
2025partial year 16 11.3%

Which technologies does NxStage Medical, Inc. patent most?

Top 15 of 34 technology areas

Where it ranks

Overall rank by patents

#2,746

of 49,997 tracked assignees

Innovation Score

54.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

NxStage Medical, Inc.'s patent record in context - here's where to go next.

  • NxStage Medical, Inc.'s lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 95% of its portfolio - see every assignee active in that class. Explore A61M
  • Ranked #2,746 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare NxStage Medical, Inc. against Kemet Electronics Corporation, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 54.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.